


RESEARCH

Vitamin D receptor expression in germinal centre type diffuse large B-cell lymphoma cells is associated with vitamin D insensitivity

Elizabeth J Soilleux^{1,2}, Amanda Anderson¹, Emma Roberts¹, Linden Lyne¹, Kah Keng Wong³, Hayley Spearman¹, Stefano Casola^{4,5}, Alison H Banham¹ and Duncan M Gascoyne^{1,2} 

¹Nuffield Division of Clinical Laboratory Sciences, Radcliffe Department of Medicine, University of Oxford, Oxford, UK

²Department of Pathology, University of Cambridge, Cambridge, UK

³Department of Immunology, School of Medical Sciences, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia

⁴Genetics of B Cells and Lymphoma Unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy

⁵University of Milan, Department of Medical Biotechnology and Translational Medicine, Milan, Lombardy, Italy

Correspondence should be addressed to D M Gascoyne: dg752@cam.ac.uk

Abstract

Objective: Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous group of non-Hodgkin lymphomas (NHLs) often sub-classified into major germinal centre (GC) and activated B-cell (ABC) cell-of-origin types. We have previously shown vitamin D receptor (VDR) expression in plasmablastic ABC-DLBCL cells and demonstrated inhibition of their growth by exogenous vitamin D (VitD3); however, the vitamin D biology of GC-DLBCL cells remained unclear.

Design/methods: Study of VDR and related molecule expression and vitamin D response across a panel of DLBCL and myeloma cell lines by western blot, qPCR, flow cytometry and cell counting techniques. Analysis of gene expression and ChIP-seq in published cell line and/or primary DLBCL datasets.

Results: We show that some BCL6^{hi} GC-DLBCL cell lines express low levels of VDR, but appear resistant to VitD3, and associate VDR positivity in both GC- and ABC-DLBCL cell lines with the poor prognosis plasmacytic/activation marker CD38. ChIP-seq data suggest that VDR may be a direct BCL6 target. Functionally, VitD3 and the EB-1089 analogue can reduce growth, inhibit MYC expression and increase CD38 expression by 50–400% on ABC-DLBCL and myeloma but not GC-DLBCL cells. CD38 is also activated by VitD3 treatment of human peripheral B cell lines, where VDR can bind to the CD38 locus, suggesting direct regulation.

Conclusions: Combined VDR and cell-of-origin assessment may contribute to a greater understanding of vitamin D's role in mature B-cell lymphoma and its interplay with BCL6 and MYC.

Keywords: vitamin D receptor (VDR); DLBCL; non-Hodgkin's lymphoma; myeloma; CD38; daratumumab; VitD3; EB-1089; MYC; growth arrest; BCL6

Introduction

There is now a significant body of clinical evidence implicating vitamin D in B-cell lymphoma and myeloma biology. Multiple studies have linked

insufficiency in circulating vitamin D levels with poor outcomes (1, 2, 3, 4, 5, 6, 7, 8), and vitamin D supplementation in patients with aggressive lymphoma

may slightly improve survival rates (8). In contrast, a recent study found no significant effect on event-free survival when patients with indolent non-Hodgkin's lymphoma were given supplemental vitamin D (9), suggesting a complex picture of vitamin D biology in lymphoma. Increased susceptibility of VDR-deficient mice to carcinogen-induced lymphoblastic lymphoma (10) might corroborate a role of active vitamin D signalling in lymphoma suppression. Many vitamin D studies have been performed with analogues, such as EB-1089, which may have improved activity without hypercalcaemic effects (11). However, despite mounting evidence for a relationship between increased circulating vitamin D and better clinical outcomes in mature B-cell malignancies, mechanisms underlying this relationship are incompletely understood and a high degree of biological heterogeneity in these diseases is likely to confound analyses.

Current evidence indicates that, at least in part, vitamin D serum levels and VDR polymorphism may be relevant in lymphoma and myeloma disease through effects of vitamin D on the VDR receptor in malignant cells. VDR expression has been described in normal lymphocytes (12, 13) and cells of multiple mature B-cell malignancies, including Hodgkin lymphoma (14), myeloma (15), and primary effusion lymphoma (PEL) (16), reviewed in (7). There is some *in vitro* evidence for anti-proliferative effects of VitD3 on myeloma and lymphoma cells (15, 17, 18), and we previously demonstrated that treatment of activated B-cell (ABC)-type DLBCL lymphoma cells with VitD3 or the low-calcaemic analogue EB-1089 reduces proliferation by approximately 30%. This effect is likely mediated via reductions in the expression of Rb, CDK4 and cyclins A2, B2, D3 and E1 and a post-transcriptional decrease in MYC protein (19). Overall, currently available data are consistent with a model in which sufficient levels of circulating vitamin D improve prognosis, at least in part, by directly inhibiting growth of lymphoma and myeloma cells. Conversely, loss of this vitamin D-dependent growth inhibition under hormone-deficient conditions may facilitate increased tumour cell proliferation.

In the heterogeneous disease DLBCL, research has identified subtypes with specific biological pathway activities that can be targeted therapeutically. The major ABC-DLBCL and germinal centre (GC)-DLBCL subtypes were originally established by gene expression profiling, and assignment of tumours to these categories has improved stratification of patients for therapy (20, 21). Tumours are now categorised clinically as GC subtype or non-GC subtype, the latter including ABC and a small proportion of unclassified/type 3 DLBCL cases. While ABC-type DLBCL features robust NF- κ B-driven IRF4 expression and chronic active B-cell receptor (BCR) signalling (22), GC-DLBCL shares with its normal counterparts expression of a large number of genes under the

control of the GC B-cell master transcription factor BCL6. While R-CHOP therapy combining anti-CD20 rituximab antibody with cytotoxic therapy has improved DLBCL outcomes, many patients still do not respond or relapse, and multiple novel therapies such as those targeting CD38 (23) have been trialled (24, 25). Advances in the understanding of DLBCL disease have been driven by complementary studies of primary patient material and multiple GC-DLBCL and ABC-DLBCL cell lines, with which detailed *in vitro* studies can be performed.

One marker highlighting the heterogeneity of DLBCL disease is CD38, a multifunctional immune activation surface protein (26) expressed consistently on myelomas (27) but on only a proportion of DLBCL (28, 29, 30). Importantly, CD38 expression is associated with poor outcomes in DLBCL (30), and while now an established therapeutic target in myeloma (31), CD38 is an evolving therapeutic target in DLBCL. In particular, CD38-targeting therapeutic strategies, such as the monoclonal antibody daratumumab, have shown modest efficacy in clinical DLBCL trials (25, 32, 33). Notably, due to these limited effects and development of resistance to CD38-targeted therapy in myeloma, therapeutic strategies enhancing CD38 expression are being actively sought (reviewed in (33)).

In the present study, we link CD38 expression in subsets of both GC- and ABC-DLBCL cell lines with that of VDR. Functionally, we find that *in vitro* VitD3 or its analogue EB-1089 are sufficient to enhance surface CD38 expression and reduce growth of myeloma and ABC-DLBCL cells, but interestingly not GC-DLBCL cells, despite their VDR expression. CD38 can be activated by VitD3 also in immortalized human B-cell lines, where liganded VDR can bind to the CD38 locus, suggesting direct regulation. Preliminary analyses suggest that in GC-DLBCL cells, VDR expression may be regulated by BCL6 via direct binding to the VDR locus and vitamin D response may be silenced via multiple mechanisms. Combined, our data support a model in which cell-of-origin subtype determines vitamin D responsiveness of DLBCL cells *in vitro* and may provide a rationale for combination of CD38 targeting in ABC-type DLBCL and multiple myeloma with vitamin D supplementation in the future.

Materials and methods

Human cell lines

Cell lines were maintained at fewer than 30 passages according to standard procedures in RPMI 1640 media supplemented with 10% foetal bovine serum and were used within 10 passages of supply or STR profiled to confirm identity, as previously (19). In vitamin D ligand experiments, cells were treated with ethanol vehicle or

10^{-7} M $1\alpha,25$ -hydroxyvitamin D (vitamin D₃/VitD3) or 10^{-7} M EB-1089 (Sigma, UK). Viability and proliferation were monitored by trypan blue exclusion dye assay and/or MTS assay (Promega, UK).

Immunohistochemistry

For immunohistochemistry, formalin-fixed and paraffin-embedded tissues were sectioned and mounted on slides before dewaxing and antigen retrieval by microwaving in 50 mM Tris and 2 mM EDTA, pH 9.0. Primary antibodies recognizing VDR (Santa Cruz, USA; clone D6 at 1:200), CD20 (in-house clone L26 at 1:20), CD38 (Vector Laboratories, UK; VP-C348 at 1:50) or isotype control (mIgG1 R&D Systems, USA; MAB002 at 1:50) were applied overnight at 4°C or room temperature for 30 min, and the EnVision system (Dako, USA) was used for detection alongside haematoxylin counterstaining (Sigma) where required. For VDR/CD20 double labelling without counterstain, immunostaining was repeated using a second primary antibody and blue substrate (Vector SG, Vector). Images were acquired using an Olympus BX51 microscope with 40× objective. Morphological analysis was performed using ImageJ software (NIH, USA). Tumour CD38 and VDR staining scores on human tumours represent approximate percentage of tumour stained multiplied by stain intensity graded 0–3.

Western blotting

Whole-cell lysates were prepared, and protein was quantitated by BCA assay (ThermoFisher Scientific, UK). 40 µg lysate was subjected to western blotting after 12% SDS-PAGE, using antibodies recognising hVDR (D-6, Santa Cruz Biotech; 1:1,000), BCL6 (191E/A8, in-house supernatant; 1:250), β-actin (AC15, Sigma; 1:20,000), MYC (D3N8F, Cell Signaling, USA; 1:1,000) or FOXP1 (JC12, in-house supernatant; 1:30). Blots were incubated in PBS containing 5% milk 0.02% Tween-20, and signals were detected using ECL reagent (GE Healthcare, UK).

Flow cytometry

Surface CD38 protein was detected by FACScalibur (BD Biosciences, UK) after staining with APC-conjugated primary antibody recognizing human CD38 (HIT-2, 17-0389-41, ThermoFisher) or APC-conjugated isotype control (mouse IgG1k, 17-4714-81, ThermoFisher).

Quantitation of gene expression

For real-time PCR analysis, total RNA was column-purified (Qiagen, UK) and 1 µg was converted to cDNA using superscript III enzyme (Life Technologies, UK). Universal MasterMix II (Life Technologies) and the following TaqMan assays (all Applied Biosystems, UK) were used for quantitative


amplification on a Chromo4 instrument (BioRad, UK): hVDR (Hs01045840_m1), hIRF4 (Hs00180031_m1), hIGF1 (Hs01547656_m1), hHPGD (Hs00960587_m1), hSLA (Hs00277129_m1), hBCL6 (Hs00153368_m1) and hIL6 (Hs00985639_m1). Normalisation was performed by the $\Delta\Delta$ Ct method using one or more VIC-labelled controls (18s – 4318839, hTBP – 4325803, and hB2M – 4326319E).

Bioinformatic analyses

DepMap (https://depmap.org/portal/data_explorer_2/) was used to examine gene transcript expression in 36 DLBCL-annotated cell lines, specifically A3KAW, A4FUK, CCLFHEME0001T, DB, DOHH2, EJ1, FARAGE, HF, HT, KARPAS422, KML1, NUDUL1, OCILY132, OCILY18, OCILY19, OCILY3, OCILY7, PFEIFFER, RC, RCK8, RI1, RL, SUDHL10, SUDHL2, SUDHL4, SUDHL5, SUDHL6, SUDHL8, TOLEDO, U2904, U2940, U2946, ULA, VAL, WILL1 and WSUNHL. Cell lines were ascribed subtype where possible based on the published literature; however, 6 ‘GC’ cell lines (OCI-Ly19, TOLEDO, SUDHL8, OCI-Ly7, RC and HF) showed uncharacteristic low or absent expression of GC marker genes *BCL6*, *SERPINA9* and *MYBL1* and robust expression of ABC marker genes *IRF4*, *XBP1* and *KCNA3* and were therefore removed from analyses showing subtype (Fig. 1F and Supplemental Fig. S9 (see section on [Supplementary materials](#) given at the end of the article)). Expression data were exported and replotted in MS Excel. For comparison of VDR and CD38 expression in primary DLBCL tumours, RNA-seq data from Yan *et al.*'s GSE147986 consisting of 107 DLBCL cases with cell-of-origin (COO) subtype information (GC-DLBCL $n = 32$, ABC-DLBCL $n = 48$ and type 3 $n = 27$) (34) were obtained from Gene Expression Omnibus (GEO), and gene expression values were log₂-transformed. For examination of potential VDR regulator expression in DLBCL subtypes, RNA-seq datasets GSE125966 consisting of 538 DLBCL (GCB-DLBCL $n = 298$, ABC-DLBCL $n = 151$ and unclassified $n = 89$) (35) and GSE147986 (34) were obtained from GEO. Expression levels of genes of interest were tested across DLBCL subtypes. To analyse VDR and BCL6 binding to VDR and CD38 loci in the human genome (version HG18), ChIP-seq data from Hatzi *et al.* (36) and Ramagopalan *et al.* (37) were inserted as custom tracks into the UCSC browser (<https://genome.ucsc.edu/>). Software GEO2R was used to analyse gene expression data (dataset GSE22176) from untreated and 36 h vitamin D₃-treated EBV-immortalised B-cells, as described in Ramagopalan *et al.*

Statistical analyses

Statistical testing for significant differences (indicated where $P \leq 0.05$ by asterisk and $P \leq 0.01$ by double asterisk) in growth arrest, *IL6* transcript and nucleus/cytoplasm ratio experiments was performed

**Figure 1**

Vitamin D receptor (VDR) protein is expressed in both GC- and ABC-type DLBCL cells. (A and B) *VDR* transcript expression (probe 840) and *BCL6* transcript expression in cultured human DLBCL cell lines, determined by $2^{-\Delta\Delta Ct}$ real-time PCR analysis after normalisation to *18S*, relative to expression in DB, $n = 3$, mean \pm SD. (C and D) Western blot analysis of human DLBCL cell lines. GC- and ABC-DLBCL blots in C were developed in parallel, representative of at least two experiments. (E) Double immunohistochemistry detecting VDR (brown) and CD20 (blue) staining of OCI-Ly8 cells. (F) DepMap analysis of *VDR* and *BCL6* transcript expression in 30 DLBCL cell lines subtyped as GC (black), ABC (grey) or unknown (white).

using Student's *t*-test in MS Excel. *q*-value for significance of *VDR* and *CD38* transcript correlation in the DepMap cell line dataset was calculated by generating individual *P*-values from comparisons of *VDR* with all '*CD*' factors, and subsequent Benjamini–Hochberg multiple testing correction using the website <https://www.sdmproject.com/>. *P*-value for significance of *VDR*/*CD38* protein correlation in primary tumours was calculated in MS Excel from correlation coefficient and sample size using the formula found at <https://www.statology.org/>. *VDR* and *CD38* transcript correlation in primary DLBCL samples was assessed using Spearman or Pearson correlation coefficients according to whether data followed non-normal or normal distribution, respectively, as determined by Shapiro–Wilk tests. Linear regression models with 95% confidence intervals were fitted to visualize their relationships for all DLBCL cases, or based on DLBCL subtypes. Multiple testing correction was conducted using the

Benjamini–Hochberg false discovery rate method, and $q < 0.05$ was considered statistically significant. Differential gene expression across DLBCL subtypes was tested using ANOVA with Holm–Šidák post hoc tests or Kruskal–Wallis tests with Dunn's post hoc tests for normal or non-normally distributed expression, respectively. Correction for multiple testing was performed using the Benjamini–Hochberg false discovery rate method, and $q < 0.05$ was considered statistically significant.

Results

Vitamin D receptor (VDR) protein is expressed in both GC- and ABC-type DLBCL cells

Having previously identified VDR expression in a subset of ABC-DLBCL cell lines with plasmablastic

characteristics (SUDHL9 and HLY-1 (19)), we screened additional DLBCL cell lines for VDR expression. Interestingly, several GC-DLBCL cell lines expressed both VDR transcript and protein, demonstrating that VDR is not restricted to plasmablastic ABC-subtype DLBCL (Fig. 1A, C, D). In this small panel, there was a trend for higher VDR transcript and protein expression in VDR+ ABC versus VDR+ GC cell lines, and in lines of both subtypes, *BCL6* transcript levels were somewhat reduced in VDR+ cell lines (Fig. 1B). Nuclear localisation of VDR protein was confirmed by immunostaining of the GC-DLBCL cell line OCI-Ly8 (Fig. 1E). The study of VDR transcripts in a wider DLBCL cell line panel ($n = 30$, DepMap) showed positivity in approximately 50% and demonstrated a striking inverse relationship between *BCL6* expression and that of VDR (Fig. 1F), confirming results from our smaller cell line cohort. Analysis of BCL6 ChIP-seq data in OCI-Ly1 GC-DLBCL cells (36) identified multiple potential regions in the VDR locus bound by BCL6 (Supplemental Fig. S1), and more detailed examination identified within the first VDR intron region (Fig. S1 red arrow) a 5'-TTCCAGGC-3' sequence matching a BCL6-binding site consensus 5'-TTCNAGG(A/C)-3' (Supplemental Fig. S2), suggesting that BCL6 may directly regulate VDR expression. An identical 5'-TTCCAGGC-3' sequence was identified in the VDR 3' region bound by BCL6, and multiple additional potential binding sites with reduced homology to the consensus were located in BCL6-bound regions of the VDR locus (data not shown).

VDR+ DLBCL cell lines frequently display blastic morphology and gene expression

VDR expression in ABC-DLBCL cells is associated with a plasmablastic-like phenotype (19), and we considered whether GC-DLBCL cells might also show this association. To test this, we compared morphology and gene expression of VDR+ and VDR^{neg} DLBCL cell lines. The most strongly VDR+ cell lines from each DLBCL subtype, OCI-Ly8 (GC-DLBCL) and HLY-1 (ABC-DLBCL), did show an increased nuclear-to-cytoplasmic ratio suggestive of blastic morphology and displayed high proliferative rates (Supplemental Fig. S3 and S4). Some VDR+ lines also exhibited stronger expression of *IRF4*, *IGF1*, *HPGD* than VDR^{neg} lines (Supplemental Fig. S5), suggestive of increased activation status. Expression of *SLA* was strongly inverse to that of VDR in all cell lines (Supplemental Fig. S5). Activated VDR has been reported to repress the NF- κ B pathway (38), and accordingly, the strongly plasmablastic cell line HLY-1 has reduced expression of many NF- κ B pathway transcripts in comparison with ABC-DLBCL cell lines OCI-Ly3 and OCI-Ly10 (Supplemental Fig. S6). Interestingly, VDR+ GC-DLBCL lines SUDHL4 and MIEU have broadly similar NF- κ B pathway transcript status to VDR^{neg} counterparts DB and Karpas-422,

suggesting a potential lack of VDR activation in these lines (Supplemental Fig. S6).

VDR+ DLBCL cell lines frequently display expression of the plasmacytic/activation marker CD38


To further investigate a potential association between VDR and an activated phenotype, we screened cell lines for expression of CD38, a surface plasmacytic/activation marker of myeloma and blastic lymphoma, and discovered a strong positive association between VDR and CD38 expression (Fig. 2A and B). A strong and significant positive relationship between CD38 and VDR transcripts in a larger panel of B-cell lymphoma cell lines was also apparent in DepMap (39) analysis (Fig. 2C). The validity of this finding was confirmed by preliminary immunohistochemical analysis of a small cohort of seventeen primary DLBCL and myeloma tumours stained previously for VDR (19) (Fig. 3A and B), and a significant positive correlation between VDR and CD38 transcript levels was also apparent in an independent primary DLBCL dataset, in both GC and ABC subtypes (Fig. 3C).

VDR+ GC-DLBCL cells are resistant to CD38 modulation by both VitD3 and EB-1089

Co-expression of VDR and CD38 in lymphoma cells led us to examine potential regulation of CD38 expression by vitamin D ligands. We treated VDR+ cell lines with VitD3 or with EB-1089, a low-calcaemic vitamin D analogue with potentially greater potency and clinical relevance (11). Importantly, both VitD3 and EB-1089 were able to significantly increase absolute CD38 expression in ABC-DLBCL and myeloma cell lines (Fig. 4A and B, lower panels, Fig. 4C), equating to increases of approximately 50–400%. Analysis of public gene expression data from duplicate/triplicate samples of six independent EBV-transformed human peripheral B lymphocyte (PBL) cell lines treated for 36 h with calcitriol/VitD3 (37) confirmed that CD38 transcripts were upregulated (Supplemental Fig. S7) and that in 2 of 2 cell lines (855 and 861) subjected to VDR ChIP-seq analysis, liganded VDR can directly bind to the CD38 locus at 2 upstream regulatory regions (Supplemental Fig. S8). In sharp contrast, VDR+ GC-DLBCL cells were resistant to VitD3-induced CD38 activation (Fig. 4A and B upper panels, Fig. 4C).

VDR+ GC-DLBCL cells are resistant to vitamin D-dependent growth inhibition, MYC inhibition and IL6 induction

Having observed resistance to vitamin D-dependent CD38 activation in VDR+ GC-DLBCL cell lines, we investigated whether these cells are deficient in other

**Figure 2**


VDR positivity is associated with CD38 expression in DLBCL cell lines. (A) Flow cytometry (log₁₀ scale) of surface CD38 expression on human DLBCL cell lines, VDR status (top) designated from data in Fig. 1; (B) mean fluorescence intensity of surface CD38 expression from experiments as in A, after subtraction of isotype value, $n = 3$, mean \pm SD; and (C) DepMap analysis of VDR and CD38 transcript expression in DLBCL cell lines.

vitamin D responses (Fig. 5). In particular, we measured vitamin D-dependent growth inhibition, MYC protein downregulation, and *IL6* upregulation, all of which we observed previously in VDR⁺ HLY-1 cells (19). Strikingly, while both vitamin D ligands significantly inhibited growth of VDR⁺ ABC-DLBCL and myeloma cell lines, such inhibition was not observed in any VDR⁺ GC-DLBCL cell line with either ligand (Fig. 5A and B). Consistent with this finding, the vitamin D-dependent downregulation of MYC protein detectable in ABC-DLBCL HLY-1 cells (19) was lacking in GC-DLBCL cell lines (SUDHL4, SUDHL6 and MIEU, Fig. 5C). Similarly, VitD3-dependent activation of *IL6* was significant in both VDR⁺ ABC-DLBCL cell lines but not in GC-DLBCL cell lines (Fig. 5D). There was no detectable binding of liganded VDR to either *MYC* or *IL6* loci in PBL lines, suggesting indirect or post-transcriptional effects on these genes in B-lineage cells (data analysed from Ramagopalan *et al.* (37), data not shown).

In summary, data presented here show VDR transcript and protein expression in approximately 50% of DLBCL cell lines. VDR expression is positively associated with that of CD38 and *in vitro* is reduced in BCL6^{hi} GC-DLBCL cells, where BCL6 can bind to the VDR locus. Critically, multiple vitamin D responses, including upregulation of CD38 and downregulation of MYC, are deficient in BCL6^{hi} GC-DLBCL cells. These findings highlight a potentially important role for VDR and the vitamin D pathway alongside BCL6 and MYC in DLBCL biology.

Discussion

CD38 is now a well-established therapeutic target in myeloma although resistance can develop (23, 27, 31, 40), and trials in DLBCL have shown limited efficacy (25, 32, 33). For these reasons, clinically feasible strategies to activate CD38 expression in these indications are desirable (reviewed in (33)).


**Figure 3**

VDR positivity is associated with CD38 expression in DLBCL tumours. (A) Representative CD38 staining of primary mature B-cell tumours previously stained for VDR expression (19); (B) comparison of semi-quantitated VDR and CD38 IHC staining on our primary tumour cohort showing a trend for positive correlation; and (C) comparison of *VDR* and *CD38* transcript expression in 107 DLBCL tumours subtyped as GC, ABC or type 3 (GSE147986 dataset) (34).

Hormone-dependent upregulation of CD38 expression in malignant haematological cells has been described previously, most notably by retinoid in myeloma cells (40), and such studies have led to some potential retinoid-driven improvements in CD38 therapy response in myeloma (41). Interestingly, activation of CD38 expression by VitD3 is a property conserved with normal B-cells and T-cells (42, 43, 44), where combined VitD3 and retinoid may have greater effect than either alone (43). Importantly, oral vitamin D supplementation has already been shown to increase the abundance of CD38+ human B-cells *in vivo* (45), and the anti-CD38 antibody response in myeloma is related to CD38 expression level (40). Our findings suggest that, subject to validation of functional effects *in vitro*, VitD3 or analogue therapy could combine with anti-CD38 therapy both in myeloma and in ABC-type DLBCL. Furthermore, given the tight interplay between vitamin D and retinoid biology, and our previous finding that RAR-related orphan receptor A (RORA) targeting can synergise with that of VitD3 (19), *in vitro* studies of

combined VitD3 and RA effect on CD38 expression may be warranted. Mechanistically, ChIP-seq and transcript analyses of data from human PBL cell lines indicate that vitamin D-mediated upregulation of CD38 occurs at the transcript level and is likely direct, with liganded VDR binding to the *CD38* locus at two distinct locations upstream of the transcription start site. Although the VDR and CD38 relationship is strong in cell lines, it is somewhat weaker in primary samples, which we believe may be due to confounding expression of both molecules in non-tumour cell types (for example, expression of VDR in epithelia and Langerhans cells (19)).


Growth inhibitory effects of vitamin D on myeloma cell lines are consistent with those described previously (15, 17), while data presented here and previously (19) show that vitamin D is also a robust inhibitor of cell division and MYC protein expression in VDR+ ABC-DLBCL cells *in vitro*. These effects provide insight into a mechanism potentially underlying inferior event-free survival in lymphoma patients with vitamin D serum insufficiency

**Figure 4**

VDR+ GC-DLBCL cells are resistant to CD38 modulation by both VitD₃ and EB-1089. (A and B) Flow cytometry (log₁₀ scale) of surface CD38 expression on human DLBCL cell lines treated for 48 h with ethanol vehicle or 10⁻⁷ M VitD₃ (panel A) or 10⁻⁷ M EB-1089 (panel B); (C) summary data from three experiments, mean ± SD. CD38 changes in all ABC-DLBCL and myeloma but not GC-DLBCL lines were statistically significant with both ligands ($P < 0.05$).

and improved prognosis in R-CHOP-treated patients following vitamin D supplementation (8). Furthermore, given the poor prognosis of MYC+ DLBCL (46), the downregulation of MYC protein expression by either VitD₃ or EB-1089 analogue observed here in ABC-DLBCL cells *in vitro* may prove to be an important way to target MYC. A post-transcriptional indirect mechanism for vitamin D targeting of MYC via the E3 ligase FBW7 (gene *FBXW7*) (47) is likely in ABC-DLBCL cells given their expression of *FBXW7* (DepMap, data not shown) and transcript-independent MYC protein

downregulation (19). In GC-DLBCL, further studies in additional cell lines will be required to understand the role of MYC translocation in impaired vitamin D responses (of the VDR+ GC-DLBCL cell lines tested for MYC downregulation, SUDHL4 and SUDHL6 both display MYC rearrangements (48), while the translocation status of MIEU is unknown). CCLE analyses indicate that mutations at threonine T58 within MYC, which can stabilize MYC protein (49), are not present in either SUDHL4 or SUDHL6 cell lines. Notably, MYC and vitamin D deficiency are both poor

**Figure 5**

VDR+ GC-DLBCL cells are resistant to vitamin D-dependent growth inhibition, MYC inhibition and IL6 induction. (A and B) Viable cell number in VDR+ lymphoma and myeloma cell cultures 48 h after plating 200,000 cells per well in 24-well plates, treated with ethanol vehicle alone or 10^{-7} M VitD₃ or 10^{-7} M EB-1089, plotted relative to vehicle treated (100%); (C) western blot analysis of MYC expression in cell lines treated as in A and B, representative of at least two experiments; (D) real-time PCR analysis of *IL6* in DLBCL cell lines treated as in A and B, determined by the $2^{-\Delta\Delta Ct}$ method after normalisation to *18S*, relative to expression in vehicle-treated SUDHL9, $n = 3$, mean \pm SD. *IL6* transcripts were not detectable in GC-DLBCL cells after 40 cycles of amplification.

prognostic factors in DLBCL, and MYC positivity in malignant cells was more frequent in patients with VitD₃ deficiency (46). This finding is consistent with *in vivo* downregulation of MYC by vitamin D.

The inability of multiple VDR+ GC-DLBCL cell lines SUDHL4, SUDHL6, MIEU and OCI-Ly8 to mediate vitamin-D dependent growth arrest at the 48 h time point after treatment with either 10^{-7} M VitD₃ or EB-1089 is both clear and intriguing. These data are consistent with a previous report using the VDR+ GC-DLBCL cell line DOHH2 (18) but contrast with a historical report (50) showing reduced SUDHL4 proliferation after 48 h vitamin D treatment. While the reasons for this discrepancy remain unclear, outgrowth of distinct SUDHL4 subclones (see, for example, CD45 high and low populations (51)) may be responsible. Importantly, our data show functional inhibition of VitD₃ response in four independent VDR+ GC-DLBCL cell lines using four independent readouts (proliferation, MYC inhibition, IL6 activation and CD38 activation). Our findings showing vitamin D resistance in some B-cell lymphoma populations may provide a partial explanation for the observed lack of clinical response to vitamin D supplementation in a recent indolent B-cell lymphoma trial (9). Interestingly, VDR expression is reduced in *BCL6*^{hi} GC-DLBCL versus *BCL6*^{low} ABC-DLBCL cell lines *in vitro*, which could indicate yet

another defect in VDR functionality in GC-DLBCL cells, one of VDR autoregulation. Mechanistically, *BCL6* itself may play a role in control of VDR expression, since it appears to bind multiple VDR regulatory sequences, including VDR autoregulatory regions (*BCL6* D8 antibody track, Supplemental Fig. S1). Interestingly, VDR and *BCL6* may also bind a common region within the first intron of *CD38* (Supplemental Fig. S8), although this would need to be confirmed in lymphoma cells. The binding of *BCL6* at multiple sites across the VDR locus in OCI-Ly1 cells suggests a potentially complex mechanism of regulation, but in contrast, there was no evidence for liganded VDR binding to the *BCL6* locus in PBL B-cell lines (analysis of data from Ramagopalan *et al.*, data not shown). Thus, in mature B lineage cells, *BCL6* may function upstream rather than downstream of VDR as has been described in THP-1 monocytes (52).

Our *in vitro* findings suggest that clinical patient stratification according to tumoural VDR expression and ABC/GC subtype status might clarify relationships between vitamin D serum levels and outcome. Given the apparently tight relationship between VDR and CD38 expression, CD38 might be used as a surrogate for VDR. In addition, the apparent distinction between VitD₃ sensitivity in different disease subtypes may override contributions of, for example, VDR polymorphism (53).




Figure 6
Schematic diagram summarizing a working hypothesis regarding distinct vitamin D and VDR biologies in DLBCL subtypes.

While growth arrest, MYC inhibition and IL6 and CD38 activation readouts all point towards inhibition of vitamin D response in VDR+ GC-DLBCL cells, it may be important to consider potential contributions of endogenous VDR functionality without exogenous ligand (54, 55). Indeed, in ABC-DLBCL (HLY-1) and myeloma (JJN-3) cell lines, VDR depletion can reduce viable cell number (19). A positive connection between VDR and proliferation is also suggested by a relatively high proliferative rate of VDR+ OCI-Ly8, SUDHL9 and HLY-1 cell lines (Supplemental Fig. S3). It will also be important to understand how our *in vitro* findings translate to more complex *in vivo* DLBCL environments.

What factors might be responsible for blocking vitamin D responses in VDR+ GC-DLBCL cells? One factor may be their relatively low VDR expression, although myeloma cell lines also have low VDR expression (19) and respond well to vitamin D, so we believe additional factors are involved. In a preliminary literature screen, we identified several factors or pathways previously linked with vitamin D resistance or response in other models (e.g. references (52, 56, 57, 58, 59)). Interestingly, we found evidence for some preferential expression of these in GC-DLBCL cell lines in DepMap analysis (Supplemental Fig. S9), and some also showed upregulated expression in primary GC- versus ABC-DLBCL samples (Supplemental Fig. S10). Conversely, *RXRA* whose protein product is required for vitamin D responses via formation of a VDR/*RXRA* heterodimer (60) showed a trend towards greater expression in IRF4+ cell lines (Supplemental Fig. S9) although no association with subtype was observed in primary samples (Supplemental Fig. S10).

Furthermore, in preliminary experiments with murine A20 lymphoma cells, specific activation stimuli appeared

sufficient to block vitamin D responses, suggesting that differential vitamin D responsiveness in GC and ABC-DLBCL cell types might be due to multiple changes driven by distinct activation histories (D. Gascoyne unpublished data). In summary, it appears that subtype-specific expression profiles of a cohort of factors, perhaps including BCL6, SPI1, and HDAC1, may be responsible for distinct vitamin D responses in GC and ABC-DLBCL (summarised in Fig. 6).

Conclusion

Overall, the present study provides an improved understanding of intersecting vitamin D and CD38 biologies in DLBCL cells clustered according to cell of origin. Findings suggest that diagnostic assessment of tumoural VDR expression matched to the widely used histopathological classification of DLBCL into GC and ABC subtypes may improve stratification of patients destined to treatments who may benefit from complementary VitD3 administration. In addition, a greater understanding of mechanisms limiting vitamin D sensitivity of GC-DLBCL cells may identify novel vulnerabilities in this disease subtype.

Supplementary materials

This is linked to the online version of the paper at <https://doi.org/10.1530/EO-25-0057>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the work reported.

Funding

This work was supported by Bloodwise (now Blood Cancer UK) that funded DMG, AA, LL, HS and EJS via Specialist Program Grants (Refs: 10044 and 13047) awarded to AHB.

Author contribution statement

DMG and AHB designed the study, conceived experiments and wrote the manuscript. DMG, AA, ER, LL, HS and EJS performed experiments and collected data; DMG, KKW, AA and EJS generated figures and analysed data. SC conceived experiments and reviewed the manuscript. All authors approved the final submitted version of the manuscript.

Ethical approval statement

Primary tumour samples were collected with informed consent in accordance with the Declaration of Helsinki, and these studies were performed under local ethical approval from Oxford University (04/Q1604/21).

Acknowledgements

The authors would like to thank Prof. Francesca Buffa (IFOM, Milan) and Prof. Heike Laman (Dept. Pathology, Cambridge) for helpful contributions.

References

- Tracy SI, Maurer MJ, Witzig TE, *et al.* Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma. *Blood Cancer J* 2017 **7** e595. (<https://doi.org/10.1038/bcj.2017.70>)
- Tretli S, Schwartz GG, Torjesen PA, *et al.* Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. *Cancer Causes Control* 2012 **23** 363–370. (<https://doi.org/10.1007/s10552-011-9885-6>)
- Drake MT, Maurer MJ, Link BK, *et al.* Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. *J Clin Oncol* 2010 **28** 4191–4198. (<https://doi.org/10.1200/jco.2010.28.6674>)
- Wang W, Li G, He X, *et al.* Serum 25-hydroxyvitamin D levels and prognosis in hematological malignancies: a systematic review and meta-analysis. *Cell Physiol Biochem* 2015 **35** 1999–2005. (<https://doi.org/10.1159/000374007>)
- Bittenbring JT, Neumann F, Altmann B, *et al.* Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. *J Clin Oncol* 2014 **32** 3242–3248. (<https://doi.org/10.1200/jco.2013.53.4537>)
- Ng AC, Kumar SK, Rajkumar SV, *et al.* Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. *Am J Hematol* 2009 **84** 397–400. (<https://doi.org/10.1002/ajh.21412>)
- Kulling PM, Olson KC, Olson TL, *et al.* Vitamin D in hematological disorders and malignancies. *Eur J Haematol* 2017 **98** 187–197. (<https://doi.org/10.1111/ejh.12818>)
- Hohaus S, Tisi MC, Bellesi S, *et al.* Vitamin D deficiency and supplementation in patients with aggressive B-cell lymphomas treated with immunochemotherapy. *Cancer Med* 2018 **7** 270–281. (<https://doi.org/10.1002/cam4.1166>)
- Friedberg JW, Brady MT, Strawderman M, *et al.* Vitamin D in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy (ILyAD): a randomized, phase 3 clinical trial. *EClinicalMedicine* 2024 **78** 102959. (<https://doi.org/10.1016/j.eclinm.2024.102959>)
- Zinser GM, Suckow M & Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. *J Steroid Biochem Mol Biol* 2005 **97** 153–164. (<https://doi.org/10.1016/j.jsbmb.2005.06.024>)
- Hansen CM, Hamberg KJ, Binderup E, *et al.* Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. *Curr Pharm Des* 2000 **6** 803–828. (<https://doi.org/10.2174/1381612003400371>)
- Provedini DM, Tsoukas CD, Deftos LJ, *et al.* 1,25-dihydroxyvitamin D3 receptors in human leukocytes. *Science* 1983 **221** 1181–1183. (<https://doi.org/10.1126/science.6310748>)
- Chen WC, Vayuvegula B & Gupta S. 1,25-Dihydroxyvitamin D3-mediated inhibition of human B cell differentiation. *Clin Exp Immunol* 1987 **69** 639–646.
- Renne C, Benz AH & Hansmann ML. Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma. *BMC Cancer* 2012 **12** 215. (<https://doi.org/10.1186/1471-2407-12-215>)
- Park WH, Seol JG, Kim ES, *et al.* Cell cycle arrest induced by the vitamin D(3) analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. *Exp Cell Res* 2000 **254** 279–286. (<https://doi.org/10.1006/excr.1999.4735>)
- Kumar A, Mohanty S, Das P, *et al.* 1, 25(OH)2 D3 induces reactivation and death of Kaposi's sarcoma-associated herpesvirus of primary effusion lymphoma cells. *Sci Rep* 2017 **7** 12438. (<https://doi.org/10.1038/s41598-017-12676-x>)
- Rossi JF, Durie BG, Duperray C, *et al.* Phenotypic and functional analysis of 1,25-dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226. *Cancer Res* 1988 **48** 1213–1216.
- Kozielewicz P, Grafton G, Kutner A, *et al.* Novel vitamin D analogues; cytotoxic and anti-proliferative activity against a diffuse large B-cell lymphoma cell line and B-cells from healthy donors. *J Steroid Biochem Mol Biol* 2016 **164** 98–105. (<https://doi.org/10.1016/j.jsbmb.2015.10.015>)
- Gascoyne DM, Lyne L, Spearman H, *et al.* Vitamin D receptor expression in plasmablastic lymphoma and myeloma cells confers susceptibility to vitamin D. *Endocrinology* 2017 **158** 503–515. (<https://doi.org/10.1210/en.2016-1802>)
- Lenz G, Wright GW, Emre NC, *et al.* Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proc Natl Acad Sci U S A* 2008 **105** 13520–13525. (<https://doi.org/10.1073/pnas.0804295105>)
- Pasqualucci L & Dalla-Favera R. SnapShot: diffuse large B cell lymphoma. *Cancer Cell* 2014 **25** 132–132 e1. (<https://doi.org/10.1016/j.ccr.2013.12.012>)
- Davis RE, Ngo VN, Lenz G, *et al.* Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature* 2010 **463** 88–92. (<https://doi.org/10.1038/nature08638>)
- van de Donk N. Immunomodulatory effects of CD38-targeting antibodies. *Immunol Lett* 2018 **199** 16–22. (<https://doi.org/10.1016/j.imlet.2018.04.005>)
- Poletto S, Novo M, Paruzzo L, *et al.* Treatment strategies for patients with diffuse large B-cell lymphoma. *Cancer Treat Rev* 2022 **110** 102443. (<https://doi.org/10.1016/j.ctrv.2022.102443>)
- Salles G, Gopal AK, Minnema MC, *et al.* Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. *Clin Lymphoma Myeloma Leuk* 2019 **19** 275–284. (<https://doi.org/10.1016/j.clml.2018.12.013>)
- Lund FE. Signaling properties of CD38 in the mouse immune system: enzyme-dependent and -independent roles in immunity. *Mol Med* 2006 **12** 328–333. (<https://doi.org/10.2119/2006-00099.lund>)
- van de Donk N, Richardson PG & Malavasi F. CD38 antibodies in multiple myeloma: back to the future. *Blood* 2018 **131** 13–29. (<https://doi.org/10.1182/blood-2017-06-740944>)
- Bras AE, Beishuizen A, Langerak AW, *et al.* CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. *Br J Haematol* 2018 **180** 292–296. (<https://doi.org/10.1111/bjh.14310>)
- Rodrig SJ, Vergilio JA, Shahsafaei A, *et al.* Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. *Am J Surg Pathol* 2008 **32** 113–122. (<https://doi.org/10.1097/pas.0b013e3180959e09>)
- Wada F, Shimomura Y, Yabushita T, *et al.* CD38 expression is an important prognostic marker in diffuse large B-cell lymphoma. *Hematol Oncol* 2021 **39** 483–489. (<https://doi.org/10.1002/hon.2904>)

- 31 Franssen LE, Stege CAM, Zweegman S, *et al.* Resistance mechanisms towards CD38-Directed antibody therapy in multiple myeloma. *J Clin Med* 2020 **9** 1195. (<https://doi.org/10.3390/jcm9041195>)
- 32 Calabretta E & Carlo-Stella C. The many facets of CD38 in lymphoma: from tumor-microenvironment cell interactions to acquired resistance to immunotherapy. *Cells* 2020 **9** 802. (<https://doi.org/10.3390/cells9040802>)
- 33 Mustafa N, Azaman MI, Ng GKG, *et al.* Molecular determinants underlying the anti-cancer efficacy of CD38 monoclonal antibodies in hematological malignancies. *Biomolecules* 2022 **12** 1261. (<https://doi.org/10.3390/biom12091261>)
- 34 Yan WH, Jiang XN, Wang WG, *et al.* Cell-of-Origin subtyping of diffuse large B-Cell lymphoma by using a qPCR-based gene expression assay on formalin-fixed paraffin-embedded tissues. *Front Oncol* 2020 **10** 803. (<https://doi.org/10.3389/fonc.2020.00803>)
- 35 Nowicka M, Hilton LK, Ashton-Key M, *et al.* Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. *Blood Adv* 2021 **5** 2945–2957. (<https://doi.org/10.1182/bloodadvances.2021004770>)
- 36 Hatzi K, Jiang Y, Huang C, *et al.* A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. *Cell Rep* 2013 **4** 578–588. (<https://doi.org/10.1016/j.celrep.2013.06.016>)
- 37 Ramagopalan SV, Heger A, Berlanga AJ, *et al.* A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. *Genome Res* 2010 **20** 1352–1360. (<https://doi.org/10.1101/gr.107920.110>)
- 38 Chen Y, Zhang J, Ge X, *et al.* Vitamin D receptor inhibits nuclear factor kappaB activation by interacting with IkappaB kinase beta protein. *J Biol Chem* 2013 **288** 19450–19458. (<https://doi.org/10.1074/jbc.m113.467670>)
- 39 Tsherniak A, Vazquez F, Montgomery PG, *et al.* Defining a cancer dependency map. *Cell* 2017 **170** 564–576 e16. (<https://doi.org/10.1016/j.cell.2017.06.010>)
- 40 Nijhof IS, Casneuf T, van Velzen J, *et al.* CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. *Blood* 2016 **128** 959–970. (<https://doi.org/10.1182/blood-2016-03-703439>)
- 41 Frerichs KA, Minnema MC, Levin MD, *et al.* Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma. *Blood Adv* 2021 **5** 5128–5139. (<https://doi.org/10.1182/bloodadvances.2021005220>)
- 42 Stoeckler JD, Stoeckler HA, Koultab N, *et al.* 1alpha,25-Dihydroxyvitamin D3 modulates CD38 expression on human lymphocytes. *J Immunol* 1996 **157** 4908–4917. (<https://doi.org/10.4049/jimmunol.157.11.4908>)
- 43 Treptow S, Grun J, Scholz J, *et al.* 9-cis retinoic acid and 1.25-dihydroxyvitamin D(3) drive differentiation into IgA(+) secreting plasmablasts in human naive B cells. *Eur J Immunol* 2021 **51** 125–137. (<https://doi.org/10.1002/eji.202048557>)
- 44 Villegas-Ospina S, Aguilar-Jimenez W, Gonzalez SM, *et al.* Vitamin D modulates the expression of HLA-DR and CD38 after in vitro activation of T-cells. *Horm Mol Biol Clin Investig* 2017 **29** 93–103. (<https://doi.org/10.1515/hmbci-2016-0037>)
- 45 Drozdenko G, Heine G & Worm M. Oral vitamin D increases the frequencies of CD38+ human B cells and ameliorates IL-17-producing T cells. *Exp Dermatol* 2014 **23** 107–112. (<https://doi.org/10.1111/exd.12300>)
- 46 Wang WT, Liang JH, Wang L, *et al.* The prognostic value of 25-hydroxy vitamin D deficiency and its interaction with c-Myc expression in diffuse large B cell lymphoma. *Ann Hematol* 2020 **99** 2377–2384. (<https://doi.org/10.1007/s00277-020-04200-5>)
- 47 Salehi-Tabar R, Memari B, Wong H, *et al.* The tumor suppressor FBW7 and the vitamin D receptor are mutual cofactors in protein turnover and transcriptional regulation. *Mol Cancer Res* 2019 **17** 709–719. (<https://doi.org/10.1158/1541-7786.mcr-18-0991>)
- 48 Deng W, Clipson A, Liu H, *et al.* Variable responses of MYC translocation positive lymphoma cell lines to different combinations of novel agents: impact of BCL2 family protein expression. *Transl Oncol* 2018 **11** 1147–1154. (<https://doi.org/10.1016/j.tranon.2018.07.007>)
- 49 Freie B, Carroll PA, Varnum-Finney BJ, *et al.* A germline point mutation in the MYC-FBW7 phosphodegron initiates hematopoietic malignancies. *Genes Dev* 2024 **38** 253–272. (<https://doi.org/10.1101/gad.351292.123>)
- 50 Hickish T, Cunningham D, Colston K, *et al.* The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. *Br J Cancer* 1993 **68** 668–672. (<https://doi.org/10.1038/bjc.1993.406>)
- 51 Brown PJ, Gascoyne DM, Lyne L, *et al.* N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells. *Haematologica* 2016 **101** 861–871. (<https://doi.org/10.3324/haematol.2016.142141>)
- 52 Nurminen V, Neme A, Ryyanen J, *et al.* The transcriptional regulator BCL6 participates in the secondary gene regulatory response to vitamin D. *Biochim Biophys Acta* 2015 **1849** 300–308. (<https://doi.org/10.1016/j.bbarm.2014.12.001>)
- 53 Gnagnarella P, Raimondi S, Aristarco V, *et al.* Vitamin D receptor polymorphisms and cancer. *Adv Exp Med Biol* 2020 **1268** 53–114. (https://doi.org/10.1007/978-3-030-46227-7_4)
- 54 Bikle DD. Vitamin D: newer concepts of its metabolism and function at the basic and clinical level. *J Endocr Soc* 2020 **4** bvz038. (<https://doi.org/10.1210/jendso/bvz038>)
- 55 Bouillon R, Verstuyf A, Mathieu C, *et al.* Vitamin D resistance. *Best Pract Res Clin Endocrinol Metab* 2006 **20** 627–645. (<https://doi.org/10.1016/j.beem.2006.09.008>)
- 56 Seuter S, Neme A & Carlberg C. Epigenomic PU.1-VDR crosstalk modulates vitamin D signaling. *Biochim Biophys Acta Gene Regul Mech* 2017 **1860** 405–415. (<https://doi.org/10.1016/j.bbarm.2017.02.005>)
- 57 Banwell CM, O'Neill LP, Uskokovic MR, *et al.* Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. *J Steroid Biochem Mol Biol* 2004 **89-90** 245–249. (<https://doi.org/10.1016/j.jsbmb.2004.03.081>)
- 58 Quarni W, Lungchukiet P, Tse A, *et al.* RIPK1 binds to vitamin D receptor and decreases vitamin D-induced growth suppression. *J Steroid Biochem Mol Biol* 2017 **173** 157–167. (<https://doi.org/10.1016/j.jsbmb.2017.01.024>)
- 59 Taber LM, Adams LS & Teegarden D. Mechanisms of nuclear vitamin D receptor resistance in harvey-ras-transfected cells. *J Nutr Biochem* 2009 **20** 629–637. (<https://doi.org/10.1016/j.jnutbio.2008.06.008>)
- 60 Kliewer SA, Umesono K, Mangelsdorf DJ, *et al.* Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling. *Nature* 1992 **355** 446–449. (<https://doi.org/10.1038/355446a0>)